MTVA - MetaVia Inc Analyst Forecast Prices
MetaVia Inc (MTVA) bases its operations on the development of neuroprotective agents in US centers, relying on patents for tissue regeneration in dementia. The business is at the beginning of a prolonged clinical trial cycle, where the asset value 17.69 remains independent of economic conditions. Environmental sustainability is confirmed by bioethics and energy efficiency, which complements this price chart on the GURU.Markets platform illustrating cost trends.
Analytical breakdowns for MetaVia Inc (MTVA)
- market price and analyst price targets:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
- financial results and valuation multiples details:
MTVA - Company Net Income|Future Profit MetaVia Inc|MTVA - P/E Multiple|Projected Price to Earnings Ratio metaviatx.com|MTVA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio MetaVia Inc|MTVA - Operating profit EBITDA|Net earnings per share (EPS TTM) MetaVia|MTVA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months metaviatx.com|MTVA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year MetaVia Inc
Summary company analytics:MTVA MetaVia Inc.
MetaVia Inc. optimizes development costs through AI and robotics-driven laboratory research automation, which directly impacts the business's fundamental value. The overall consensus valuation of the stock on GURU.Markets aggregates average expert price targets, reflecting the discounting of logistic risks and raw material costs, allowing investors to determine the asset's degree of overvaluation relative to its real potential.
Competitors of MetaVia Inc
Consensus Target biogen.com BIIB|Neurocrine Biosciences, Inc. - Consensus Target|Analyst Forecast Prices RGC (Regencell Bioscience Ltd)|AXSM: Consensus Target|ACAD: Price Target Chart|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Consensus Target Alector Therapeutics (ALEC)|Analyst Consensus Forecast ANNX|OMER - Average Forecast Price|Neurogene Corp - Consensus Target|Analyst Forecast Prices ACIU (AC Immune Inc)|Voyager Therapeutics - Analyst Consensus Forecast|NMRA - Analyst Consensus Forecast|SCLX (Scilex) - Consensus Target|TVGN (Tevogen Bio Holdings Inc.) - Price Target Chart|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|cogrx.com (CGTX) - Analyst Median Target|Analyst Consensus Forecast IKT|Analyst Consensus Forecast cassavasciences.com (SAVA)|Assertio - Consensus Target|Fair Value Consensus COYA|VistaGen Therapeutics Inc - Analyst Consensus Forecast|Analyst Median Target Ovid Therapeutics Inc. OVID|Acumen Pharmaceuticals (ABOS) - Price Target Chart|Broker Consensus Forecast CRVO|ATHE (Alterity Therapeutics Ltd.) - Analyst Consensus Forecast|Consensus Target Clene Nanomedicine (CLNN)|Price Target Chart PepGen Inc. (PEPG)|Consensus Target jupiterneurosciences.com JUNS|Relmada Therapeutics - Consensus Target|Analyst Forecast Prices ANVS (annovisbio.com)|GRCE: Consensus Target|AIFF: Price Target Chart|KLTO: Analyst Consensus Forecast|NeuroSense Therapeutics Ltd. (NRSN) - Analyst Consensus Forecast|Price Target Chart Reviva Pharmaceuticals|Broker Consensus Forecast NRXS (neuraxis.com)|Analyst Consensus Forecast HSDT|PASG - Average Forecast Price|Neuphoria Therapeutics - Consensus Target|Analyst Consensus Forecast Minerva NERV|ATHA - Price Target Chart|Fair Value Consensus ADXN (addextherapeutics.com)|alzamend.com (ALZN) - Price Target Chart|Average Forecast Price Cyclerion Therapeutics, Inc. (CYCN)|Price Target Chart Protagenic Therapeutics Inc.|Consensus Target Pasithea (KTTA)|Analyst Consensus Forecast CRGT|ATXI - Average Forecast Price|BrainStorm Cell Therapeutics - Consensus Target|Analyst Forecast Prices CARA (Cara Therapeutics Inc.)|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|ELYM - Analyst Consensus Forecast|ITCI (intracellulartherapies.com) - Consensus Target|LBPH (longboardpharma.com) - Price Target Chart|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|NKGen Biotech Inc (NKGN) - Analyst Median Target|Analyst Consensus Forecast NRBO|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Synaptogenix, Inc. - Consensus Target|Fair Value Consensus TRVN|Vigil Neuro - Analyst Consensus Forecast|Analyst Median Target Anew Medical Inc. WENA|Cerevel (CERE) - Price Target Chart
